Evidence map›Paper›PMID 42032449›Full record

ArticleCancer science2026

T Cell Heterogeneity Shaped by Alternative Splicing Predicts Prognosis in Hepatocellular Carcinoma.

Xiaohui Peng, Zhenli Li, Xiuqing Dong, Zhixiong Cai, Chenfan Lu, Junjie Gao, Shuyue You, Yuwen Wang, Jianming Mao, Xiaolong Liu and 2 more

Abstract read
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaohui PengThe School of Public Health, Fujian Medical University, Fuzhou, China.
Zhenli LiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Xiuqing DongThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Zhixiong CaiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Chenfan LuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Junjie GaoThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Shuyue YouThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Yuwen WangThe School of Public Health, Fujian Medical University, Fuzhou, China.
Jianming MaoThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Xiaolong LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0002-3096-4981
Geng ChenThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Yingchao WangThe School of Public Health, Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0003-3590-9233

Funding

Fujian Provincial Health Science and Technology Plan Project 2023CXA050National Natural Science Foundation of China 82303965Natural Science Foundation of Fujian Province 2024J011217
6 · The paper itself

Abstract

Alternative splicing (AS) plays a key role in the regulation of immune function and cellular heterogeneity. However, its impact on T-cell behavior and clinical outcomes in hepatocellular carcinoma (HCC) remains poorly understood. Single-cell full-length transcriptome data were used to obtain comprehensive splicing site information. Variable AS events were identified in each cell using the SCASL algorithm, and AS-based profiles were constructed. Based on this, differential expression, functional enrichment, cell interaction, and RNA velocity analyses were used to reveal functional differences among distinct cell populations based on AS profiles. Finally, based on the functional differences among distinct T-cell subpopulations, an AS event-based survival prognosis model was constructed to assess patient outcomes. Using the SCASL algorithm, major cell subpopulations were identified and T cells were further divided into two AS-based subtypes distinct from gene expression clustering. Functional analysis revealed that these subtypes were enriched in NOD-like receptors, C-type lectin receptors, T-cell receptor signaling, antigen processing and presentation, and other immune-related pathways. Based on the definition of AS events, we constructed a prognostic model capable of distinguishing between patients with different risk levels, which was further validated using public datasets. Collectively, our findings highlight the crucial role of AS in shaping T-cell functional heterogeneity, and the AS-based prognostic model we established further underscores its clinical relevance, providing novel insights into tumor-immune interactions and uncovering potential splicing-derived biomarkers for immunotherapy.

Indexed as

Alternative SplicingCarcinoma, HepatocellularLiver NeoplasmsT-LymphocytesAlgorithmsBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisSingle-Cell Gene Expression AnalysisTranscriptomeBiomarkers, Tumoralternative splicinghepatocellular carcinomaprognosisT‐cell immunitytumor immune microenvironment

Identifiers

PMID42032449
PMCPMC13327004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.